MNOV Stock Forecast: MediciNova, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for MediciNova, Inc. is $8. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 88 of 100 as at 21 Nov 2026 — inside the top quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores MediciNova, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (89): The share price has been relatively steady.
Issuance (37): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MNOV stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MNOV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Sept 2026 | Roth Capital | Initiates | Buy | $6.00 |
| 4 May 2026 | D. Boral Capital | Maintains | Buy | $9.00 |
| 23 Mar 2026 | Maxim Group | Reinstates | Buy | $6.00 |
| 16 Mar 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 30 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 18 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 8 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 31 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 22 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 24 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 June 2025 | B. Riley Securities | Maintains | Buy | — |
| 9 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 6 Dec 2024 | D. Boral Capital | Maintains | Buy | — |
| 2 Dec 2024 | D. Boral Capital | Initiates | Buy | — |
| 10 Mar 2021 | Maxim Group | Initiates | Buy | — |
| 13 Mar 2020 | B. Riley FBR | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MNOV.
This page is one stock. Monday covers all of them.
MNOV appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MNOV vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, MediciNova, Inc. returned −7.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MNOV analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 71.7×
- Price / book
- 1.6×
- EV / EBITDA
- —
Cheaper than 4% of US stocks
Cheaper than 51% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 69.3%
- Operating margin
- —
- Net margin
- —
Higher than 82% of US stocks
- Return on equity
- −24.8%
- Return on assets
- −15.5%
- Dividend yield
- —
Higher than 30% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MediciNova, Inc. has a market value of $67.1M and an enterprise value of $38.4M.
Revenue in the twelve months to 30 June 2026: $920K. The latest quarter grew 240.6% year on year.
Net income over the same four quarters: −$10.8M, a −1168.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$9.1M.
MediciNova, Inc. employs 6 people — $153K of revenue per employee.
Data provided by Twelve Data
MNOV and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MNOV’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own MediciNova, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MNOV
What is the MNOV stock price forecast for 2026-2027?
The median 12-month analyst price target for MediciNova, Inc. is $8, with estimates ranging from $6 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MNOV stock a buy right now?
Of the 4 analysts covering MediciNova, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MediciNova, Inc. 88 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MNOV?
As at 21 Nov 2026, MediciNova, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (89 of 100).
Will MNOV stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $8, and Ticker Nerd's factor model ranks MediciNova, Inc. 88 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MNOV stock forecast for 2030?
No analyst covering MediciNova, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MNOV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $11 over the next 12 months.
How has MNOV stock performed over the past year?
MediciNova, Inc. returned -7.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does MediciNova, Inc. do?
MediciNova Inc. is a biopharmaceutical company focused on developing novel small-molecule therapeutics for serious diseases with unmet medical needs. MediciNova’s current programs center on neurology, respiratory disease, and liver-related conditions, with development efforts concentrated on candidates such as MN-166 (ibudilast), MN-001 (tipelukast), and MN-221.
About MediciNova, Inc.
MediciNova Inc. is a biopharmaceutical company focused on developing novel small-molecule therapeutics for serious diseases with unmet medical needs. MediciNova’s current programs center on neurology, respiratory disease, and liver-related conditions, with development efforts concentrated on candidates such as MN-166 (ibudilast), MN-001 (tipelukast), and MN-221. Its pipeline targets a range of disorders including neurodegenerative, inflammatory, fibrotic, metabolic, and respiratory diseases, reflecting a portfolio built around differentiated mechanisms of action and clinical development across multiple indications. The company works through strategic alliances and clinical collaborations to advance its programs and support drug development from early research through later-stage trials. Headquartered in La Jolla, California, MediciNova Inc. occupies a specialized role in the biotechnology market by pursuing therapies for complex conditions where current treatment options remain limited.
CEO Dr. Yuichi Iwaki M.D., Ph.D. · 6 employees · United States · https://medicinova.com